Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron and keeping the price target at $725.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Regeneron’s promising outlook. The recent approval of Eylea HD for retinal vein occlusion (RVO) and the expanded dosing flexibility to every four weeks (Q4W) is a significant positive development. This approval not only enhances the product’s profile but also provides physicians with increased treatment flexibility, which is crucial for patient management and reimbursement considerations.
Furthermore, the approval was unexpected given previous regulatory challenges, signaling an improvement in Regeneron’s ability to navigate these hurdles. Despite past setbacks, such as complete response letters and manufacturing issues, these recent approvals mark a step forward in overcoming obstacles for Eylea HD. Additionally, Seigerman’s positive outlook is supported by Regeneron’s strong base business, promising oncology franchise, and potential in their early-stage pipeline, which collectively contribute to the company’s long-term success in the biotech industry.
According to TipRanks, Seigerman is a 4-star analyst with an average return of 7.1% and a 50.56% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Pfizer, and Novo Nordisk.
In another report released yesterday, Bernstein also assigned a Buy rating to the stock with a $818.00 price target.